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ABSTRACT 17 
Plasmodium falciparum causes the most severe and fatal form of malaria in humans with over half a million 18 
deaths each year. Cerebral malaria (CM), a complex neurological syndrome of severe falciparum malaria, is 19 
often fatal and represents a major public health burden. Despite vigorous efforts, the pathophysiology of CM 20 
remains to be elucidated, thereby hindering the development of adjunctive therapies. In recent years, 21 
multidisciplinary and collaborative approaches have led to groundbreaking progress both in the laboratory and 22 
in the field. Here we review the latest breakthroughs in severe malaria pathogenesis, with a specific focus on 23 
new pathogenetic mechanisms leading to CM. The most recent findings point towards specific parasite 24 
phenotypes targeting brain microvasculature, endothelial dysfunction and subsequent oedema-induced brain 25 
swelling. 26 
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1. Introduction 33 
Malaria is still a leading cause of morbidity and mortality in the developing world. The virulence of 34 
Plasmodium falciparum is caused by several factors including parasite proteins on the surface of infected 35 
erythrocytes (IE). These allow the binding of these cells to the microvascular endothelium of various organs 36 
and tissues during infection. Proteins of the P. falciparum erythrocyte membrane protein 1 (PfEMP1) family 37 
mediate this adhesion through specific binding to multiple cell receptors. These include intercellular adhesion 38 
molecule-1 (ICAM-1), CD36, E-selectin, neural cell adhesion molecule (NCAM) and CD31 (PECAM-1) for 39 
endothelial beds, as well as chondroitin sulfate A (CSA) for placental syncytiotrophoblasts. Binding to 40 
endothelium results in widespread sequestration of IE, which can lead to lead to endothelial activation as well 41 
as pro-inflammatory and pro-coagulant responses.  42 
Severe falciparum malaria encompasses a broad range of diseases, the development of which may be 43 
influenced by age, exposure and immune status (Wassmer et al., 2015). It includes complications that affect 44 
specific organs such as the brain in cerebral malaria (CM) or the placenta in malaria in pregnancy (MiP). 45 
Histopathology and laboratory studies allowed investigators to establish a causal link between placenta-46 
specific sequestration of P. falciparum and MiP. Indeed, the ability of PfEMP1 variants to target different 47 
receptors, the expression of which varies depending on the organ, could explain why some patients with 48 
malaria develop organ-specific syndromes. Researchers have speculated that a specific PfEMP1 variant could 49 
bind receptors that are preferentially expressed in cerebral microvasculature, and could account for the focal 50 
manifestations observed in CM, the most lethal complication of P. falciparum infection. Two recent reports 51 
simultaneously shed new light on the pathogenetic mechanisms leading to CM. First, endothelial protein C 52 
receptor (EPCR) was identified as a binding partner for PfEMP1. Second, normally low levels of EPCR in brain 53 
microvessels were shown to be further down-regulated in CM, with a loss of EPCR and thrombomodulin at 54 
sites of IE sequestration. These studies provided new clues towards parasite and host cell interactions leading 55 
to CM, and connected for the first time brain-specific sequestration of EPCR-binding parasites to the loss of the 56 
protein C anti-coagulant function and endothelial cytoprotective pathways (Aird et al., 2014).  57 
While the relative frequency of severe malaria is low, its reported case fatality rate has not substantially 58 
changed over decades, especially for CM (Manning et al., 2014). Due to the lack of specific neuro- and 59 
vasculoprotective therapies, treatments for CM are currently still precariously limited to antimalarial drugs and 60 
emergency supportive care. The former are quickly dwindling, as the resistance of P. falciparum malaria 61 
against artemisinin combination treatments, the recommended first-line therapy for infected patients, is on the 62 
rise in southeastern Asia. Multi-drug-resistant falciparum malaria is increasingly difficult to treat and new 63 
antimalarials are not expected to become available within the next few years. This underlines the necessity for 64 
molecular markers for surveillance of partner drug resistance, in conjunction with the implementation of new 65 
biomarkers for early diagnosis and outcome prediction, as well as effective adjunct therapies.  66 
Here we review some recent data with a focus on newly developed research approaches aimed at a better 67 
understanding of the pathogenetic mechanisms of severe malaria in general and CM in particular.  68 
 69 
2.  Parasite-brain microvasculature specificity in CM: a virulence factor? 70 
The severity of P. falciparum is linked to sequestration of IEs within the microvasculature of various organs 71 
including the brain. This sequestration is driven both by the expressed var gene in the parasite, leading to the 72 
expression of a specific variant of PfEMP-1, and the presence of its associated receptors on microvascular 73 
walls (Hviid and Jensen, 2015). Since there are considerable variations in both adhesion molecule expression 74 
and functional properties of endothelial cells depending on their position within the vascular bed of a particular 75 
tissue, it has been hypothesised that CM may result from a brain endothelial-specific adhesive type of parasite 76 
(Moxon et al., 2014). Indeed, IE expressing the domain cassettes (DC) 8 and 13 of the cytoadherent ligand 77 
PfEMP-1 adhere to EPCR (Turner et al., 2013). By interfering with EPCR anti-coagulant and pro-endothelial 78 
barrier functions, IE adhesion could promote coagulation and vascular permeability that contribute to the 79 
pathogenesis of CM (Moxon et al., 2014). To better understand parasite factors that contribute to disease 80 
severity, Gillrie et al. (2015) developed in vitro binding models for different microvascular beds to examine the 81 
adhesion of DC8- and DC13-expressing parasite lines to endothelial cells from different microvasculature, and 82 
the consequences of EPCR engagement on endothelial cell function. They reported that IE from IT4var19 83 
(DC8) and IT4var07 (DC13) parasite lines adhere to human brain, lung and dermal endothelial cells under 84 
shear stress. However, the relative contribution of EPCR to parasite cytoadherence on different types of 85 
endothelial cell varied.  86 
Divergent functional outcomes for DC8 cysteine-rich interdomain region (CIDR) α1.1 and DC13 CIDRα1.4 87 
domains were also observed. IT4var07 CIDRα1.4 inhibited generation of activated protein C (APC) on lung 88 
and dermal endothelial cells and blocked the APC-EPCR binding interaction on brain endothelial cells. 89 
IT4var19 CIDRα1.1 inhibited thrombin-induced endothelial barrier dysfunction in lung endothelial cells, 90 
whereas IT4var07 CIDRα1.4 inhibited the protective effect of APC on thrombin-induced permeability. Overall, 91 
these findings reveal a much greater complexity of how CIDRα1-expressing parasites may 92 
modulate malaria pathogenesis through EPCR adhesion (Gillrie et al., 2015). DC8 PfEMP1 encode multiple 93 
endothelial binding domains, including binding activity for EPCR. These results show that PfEMP1 domains 94 
compete with protein C for EPCR binding but the extent of competition differs between domains. 95 
Bernabeu et al. (2016) recently investigated these parasite virulence factors in adult patients in India and 96 
demonstrated that specific EPCR-binding parasites lead to severe malaria in that population. In addition, 97 
parasite phenotype and biomass are associated with patient hospitalization and disease severity. The authors 98 
show a broad range of EPCR binding activity from severe malaria isolates and even parasite domains that 99 
partially obstructed the interaction between EPCR and APC were sufficient to interfere with the cytoprotective 100 
functions of APC (Bernabeu et al., 2016). Taken together, their findings suggest that parasites may be under 101 
selection for phenotypic variation in a key host pathway that regulates coagulation and endothelial barrier 102 
properties, and has important implications for pathogenic mechanisms in severe malaria. Full‐ length 103 
sequences of PfEMP1 encoding transcripts were characterized in clinical isolates from children with severe 104 
malaria admitted to hospital in Tanzania, and EPCR-binding CIDRα1 domains dominated PfEMP1 transcript 105 
profiles of children suffering from CM and/or severe malarial anaemia, further strengthening the evidence for a 106 
crucial pathogenic role of the PfEMP1–EPCR interaction in severe malaria (Jespersen et al., 2016).  107 
EPCR is not the only receptor suspected to play an important role in the development of severe malaria. 108 
Studies of parasite isolates have demonstrated high rates of in vitro ICAM-1 binding among wild strains but 109 
reported correlations between ICAM-1 binding and disease severity have been inconsistent. Recent results 110 
suggest that ICAM-1 is a co-receptor for a subset of EPCR-binding parasites (Avril et al., 2016). Indeed, Avril 111 
et al. (2016) showed that parasites expressing DC13 have dual binding specificity for EPCR and ICAM-1, 112 
suggesting for the first time that ICAM-1-binding variants can be grouped into CD36 and EPCR co-receptor-113 
binding traits. This leads to different cytoadherence abilities on TNF-stimulated endothelial cells, which has 114 
important implications for understanding parasite organ-specific microvascular bed tropism in pro-inflammatory 115 
conditions. 116 
 117 
3.  Microvascular endothelial dysfunction: new causes and repercussions 118 
In the recent years, convincing evidence has been presented to support the role of both endothelial cell 119 
activation and platelets in modulating the pathogenesis of severe P. falciparum malaria. Thrombin, a common 120 
factor in both processes, is now thought to be a driver of pathology in CM. The relative contribution of EPCR-121 
binding parasites versus loss of EPCR from the endothelial surface in mediating CM is not known, although 122 
both are associated with disease in clinical studies (Turner et al., 2013; Moxon et al., 2014). The key mediator 123 
of inflammation in both cases appears to be thrombin, which is a potent mediator of both pro-and anti-124 
inflammatory pathways, depending on the context of endothelial signalling. Thrombin engages thrombomodulin 125 
on the plasma membrane of intact endothelium, where it promotes activation of protein C. The latter is 126 
accelerated by the presence of EPCR, which binds to protein C and presents it for optimal activation by the 127 
thrombin-thrombomodulin complex. Further to its anticoagulant activity, generated APC can also trigger 128 
numerous cell-signaling pathways initiating protective cellular responses upon exposure to pro-inflammatory, 129 
pro-apoptotic, or toxic insult. IEs expressing PfEMP1 compete with protein C and APC for EPCR, thereby 130 
down-regulating protein C activation by the thrombin-thrombomodulin complex. The resulting loss of EPCR-131 
APC–induced cytoprotective signalling is consistent with a decrease in blood-brain barrier (BBB) properties, 132 
potentially leading to vasogenic oedema in CM.   133 
Direct protein C pathway alteration by binding of EPCR-specific IEs is not the only cause of endothelial 134 
dysfunction in CM. Indeed, P. falciparum infection also initiates early endothelial and platelet activation, leading 135 
to coagulation dysregulation and microvascular lesions locally (Wassmer et al., 2011a). Furthermore, IEs elicit 136 
a myriad of signalling pathways leading to aberrant pro-coagulant effects, ultimately resulting in enhanced 137 
endothelial activation, damage and apoptosis (O'Sullivan et al., 2016). Lastly, severe falciparum malaria has 138 
been associated with a down-regulation of normal endogenous anticoagulant pathways. EC surface 139 
expression of thrombomodulin and EPCR are both reduced, likely through cytokine-enhanced shedding, 140 
leading to an increase of their soluble levels in plasma (Moxon et al., 2013). Together, these effects combine 141 
and lead to a significant reduction in generation of anti-inflammatory and cytoprotective APC on the endothelial 142 
surface. These findings suggest new avenues for acute therapeutic intervention and match well with post-143 
mortem observations and magnetic resonance imaging (MRI) findings linked to mortality in CM. 144 
Such an endothelial dysfunction is not only observed in severe falciparum malaria, but was also reported in 145 
severe Plasmodium vivax (Barber et al., 2015) and Plasmodium knowlesi (Yeo et al., 2007) cases, which 146 
raises the question of possible common pathogenic pathways in these various types of infection. All plasmodia  147 
species can cause severe and fatal malaria. In falciparum malaria, the most common cause of severe malaria, 148 
impaired tissue perfusion has long been recognised to arise from microvascular obstruction by IE adherent to 149 
endothelial cells. More recently recognised is the contribution of concurrent impairment of nitric oxide (NO) 150 
bioavailability, endothelial activation and microvascular dysfunction to impaired tissue perfusion and severe 151 
disease (Yeo et al., 2014). Angiopoietin-2, released from endothelial cell Weibel-Palade bodies and an NO-152 
inhibited autocrine mediator of endothelial activation, is markedly elevated in severe falciparum malaria and 153 
consistently associated with impaired tissue perfusion and fatal outcome in both adult and paediatric severe 154 
malaria. This is independent of both total and sequestered parasite biomass, suggesting that microvascular 155 
obstruction and microvascular dysfunction make separate contributions to pathogenesis. Microvascular 156 
function, the capacity to increase flow and oxygen delivery in response to ischaemia, is decreased in severe 157 
falciparum malaria and associated with an increased risk of death. Endothelial activation, decreased 158 
endothelial NO bioavailability and microvascular dysfunction are also associated with impaired tissue perfusion 159 
in vivax and knowlesi malaria, a factor likely to contribute to organ dysfunction and severe malaria caused by 160 
infection with these species. Initial clinical trials of agents aimed at restoring NO bioavailability in severe 161 
falciparum malaria have recently been completed (Hawkes et al., 2011; Serghides et al., 2011), and 162 
microvascular function can be improved by L-arginine infusion in severe falciparum malaria (Yeo et al., 2013). 163 
These results suggest that new compounds aimed at increasing microvascular NO and microvascular 164 
functions have potential clinical benefits as adjunctive treatments in severe malaria from all species. 165 
 166 
4. Rosetting and clumping: consequences for sequestration and microvascular obstruction 167 
 Parasite adhesion interactions in severe falciparum malaria are not restricted to the endothelium. Indeed, 168 
IEs can bind uninfected erythrocytes to form rosettes (Handunnetti et al., 1989), or platelets to form clumps 169 
(Pain et al., 2001). Both processes have been associated with severe malaria (Rowe et al., 1995; Pain et al., 170 
2001) and CM (Carlson et al., 1990; Wassmer et al., 2008).  171 
 In this context, recent advances have been made in elucidating the molecular mechanisms underlying 172 
rosetting, with a view to development of rosette-reversing therapies. Rosetting generally requires the presence 173 
of soluble serum factors such as IgM, and the ability of IE to form rosettes and to bind non-immune IgM is 174 
correlated (Rowe et al., 2002). While the role of IgM binding in rosetting remains unclear, it appears to 175 
strengthen the bond of the central IE with the surrounding erythrocytes. Stevenson et al. (2015) recently 176 
reported that the serum protein α2-macroglobulin (α2M) is able to induce rosetting in vitro and ex vivo, using 177 
several parasite isolates. In contrast to IgM, α2M elicits rosetting alone, while the presence of IgM significantly 178 
lowers the concentration of α2M required. The authors of the study postulate that α2M allows the crosslinking of 179 
several individual PfEMP1 molecules, thereby increasing their combined avidity for carbohydrate receptors on 180 
surrounding erythrocytes and promoting the formation of rosettes. These results suggest that 181 
P. falciparum hijacks soluble host proteins for its own benefit, and avoids immune destruction by manipulating 182 
those to facilitate adhesion of IEs to low-affinity carbohydrate receptors. In addition, another report recently 183 
showed that PfEMP1 is not the only parasite ligand used in rosetting, potentially opening new rosette-184 
disrupting approaches. Goel et al. (2015) showed in a very elegant study that the repetitive interspersed family 185 
of proteins (RIFINs) mediates binding of IEs with a preference for blood group A, leading to the formation of 186 
large rosettes of 10 or more IEs. This was not observed with IEs from group O. Indeed, blood group O is 187 
common in malaria endemic areas and IEs of that blood group were shown to form small, weak rosettes (Rowe 188 
et al., 2007). The role of RIFINs was confirmed by the disruption of rosettes in the presence of anti-RIFIN 189 
antibodies. These results suggest that RIFINs not only play a fundamental role in the development of severe 190 
malaria but also contribute to the virulence of P. falciparum.  191 
 Puzzlingly, formed rosettes have never been described in the peripheral bloodstream, suggesting that they 192 
sequester in the microvasculature and aggravate microvascular obstructions during severe malaria in general, 193 
and CM in particular. Understanding the mechanisms by which rosettes sequester (i.e., by direct binding of 194 
rosetting IE to endothelial cells, to platelets on endothelial cells or to non-rosetting cytoadherent IE is 195 
fundamental, as it may open new adjunct therapies to reduce the biomass of sequestered IE, a parameter 196 
associated with disease severity (Hendriksen et al., 2012). IE of the IT/R29 strain expressing a rosette-197 
mediating PfEMP1 variant (IT4var09) were recently shown to cytoadhere to human brain microvascular 198 
endothelial cells using heparan sulfate proteoglycans as ligands (Adams et al., 2014). This process is distinct 199 
from rosetting, which is primarily mediated by interactions with between the NTS-DBL1α domain of PfEMP1 200 
and complement receptor 1. This study shows for the first time that IT4var09-expressing parasites are capable 201 
of dual interactions with both endothelial cells and uninfected erythrocytes via distinct receptor-ligand 202 
interactions, and therefore could aggravate microvascular obstruction in severe malaria by facilitating the 203 
sequestration of platelet-mediated clumps. 204 
 One of the most recently described P. falciparum cytoadherence phenotypes is the ability of IEs to bind to 205 
platelets in suspension in vitro to form platelet-mediated clumps. Similar to rosetting, the formation of clumps is 206 
a common phenotype and has been reported in a variety of endemic settings (Rowe et al., 2009). This is 207 
mediated by the binding of IEs to platelet receptors which include CD36 (Pain et al., 2001), P-selectin 208 
(Wassmer et al., 2008) and globular C1q receptor (gC1qR) (Biswas et al., 2007). In all cases, the parasite 209 
ligands are unknown, although PfEMP1 is a likely candidate molecule. A recent study performed using clinical 210 
isolates from Mozambican patients to evaluate cytoadherence properties such as platelet-mediated clumping, 211 
rosetting and adhesion to purified receptors (CD36, ICAM1 and gC1qR) revealed that, compared with matched 212 
controls, prevalence of both rosetting and platelet-mediated clumping and adhesion to gC1qR was higher in 213 
severe cases (Mayor et al., 2011). Inhibition of these cytoadherence phenotypes may therefore reduce the 214 
occurrence or improve the prognosis of severe malaria outcomes. Similar to rosettes, platelet-mediated clumps 215 
have not been observed in the bloodstream and it is likely that they sequester in the microvasculature using IE 216 
or platelet receptors (or both) to cytoadhere on endothelial cells (Wassmer et al., 2011a). Since this may 217 
potentially aggravate microvascular obstruction in CM, further studies aimed at understanding the molecular 218 
process involved in their sequestration are warranted.  219 
 220 
5. Clinical consequences of BBB opening in CM: vasogenic oedema and brain swelling  221 
Following the report by Seydel et al. (2015), a study was initiated to investigate the different mechanisms 222 
potentially responsible for brain swelling in both pediatric and adult CM patients in India (Wassmer et al., 223 
2015). Brain swelling was identified by MRI in over 50% of patients enrolled in the ongoing study, irrespective 224 
of their age group. The frequent occurrence of brain swelling in CM has been previously reported in separate 225 
studies on Indian adults using computed tomography (CT) (Mohanty et al., 2011), as well as in Bangladeshi 226 
adults (Maude et al., 2014) and Malawian children using MRI (Potchen et al., 2012). The cause of the swelling, 227 
which can lead to brain herniation in fatal cases (Seydel et al., 2015), remains to be identified and may be due 228 
to cytotoxic or vasogenic causes. Recent results show that patients who develop CM exhibit an over-reaction 229 
of their endothelial cells to systemic inflammation, which is not observed in uncomplicated malaria (Wassmer 230 
et al., 2011b). Such vulnerability, coupled to a loss of cytoprotective EPCR in the brain, could lead to a 231 
disruption of the BBB and the leakage of fluids and proteins from the vascular system into 232 
the extracellular space. Also called vasogenic oedema, this process is consistent with the description of ring 233 
haemorrhages, a characteristic sign of BBB disruption, in pediatric CM (Taylor et al., 2004; Dorovini-Zis et al., 234 
2011). In addition, these ring hemorrhages correlate positively between retinal and cerebral tissues, owing to 235 
their common embryological origin from the neuroectoderm (Barrera et al., 2015; Greiner et al., 2015). Malaria 236 
retinopathies seen in pediatric CM are therefore a direct reflection of the neurovascular disease process, and 237 
the high frequency of ring haemorrhages both in the brain and in the retina in fatal disease point towards the 238 
occurrence of vasogenic oedema. However, evidence for a generalised increase in BBB permeability leading 239 
to vasogenic oedema is still debated. A study performed in Thailand showed no evidence of BBB impairment, 240 
as radioactively-labelled albumin given intravenously was not found in the cerebrospinal fluid (CSF) of CM 241 
patients during coma (Warrell et al., 1986). Additionally, post-mortem analyses of adult Vietnamese patients 242 
who died of CM showed that its pathophysiology only involved subtle functional changes in BBB integrity 243 
(Brown et al., 2000), and evidence from a different cohort demonstrated that localised loss of vascular integrity 244 
did not correlate with the occurrence of pre-mortem coma (Medana et al., 2011). Brain swelling may also occur 245 
as a result of cytotoxic oedema, which can result from cells in the cerebral tissue being unable to maintain 246 
membrane potential after the failure of Na+/K+ ATP-dependent pumps, due to hypoxia or nutrient deprivation. 247 
This may cause a redistribution of water from the extra-cellular to the intracellular compartments, ultimately 248 
leading to cell swelling, cell death and tissue damage. Ischaemic or hypoxic insults due to mechanical effects 249 
of microvascular obstruction by IEs, rosettes and platelet-mediated clumps, as well as nutrient “steal” by local 250 
metabolically active parasites could account for cytotoxic oedema in CM. This mechanism is consistent with 251 
abundant sequestration in the cerebral microvasculature during the neurologic syndrome (White et al., 2013), 252 
and the first in vivo magnetic resonance study of experimental CM revealed a preponderant role for cytotoxic 253 
oedema in fatal outcome (Penet et al., 2005).  254 
An increase in intravascular fluid volume within the brain due to sludging of blood flow with sequestration of 255 
IEs, rosettes and platelet-mediated clumps could also cause brain swelling and would explain the diffuse mild 256 
brain swelling reported in severe malaria patients from Bangladesh (Maude et al., 2014), without evidence of 257 
either cytotoxic or vasogenic oedema. However, cytoadherence itself may not be directly or solely responsible 258 
for this clinical syndrome (Storm and Craig, 2014).  259 
Lastly, it is entirely plausible that both mechanisms are not mutually exclusive. A study in live mice using 260 
high-field MRI with whole-brain coverage showed that vasogenic oedema occurs first in infected animals, and 261 
starts in the olfactory bulb before spreading deeper into the brain along a specific path called the rostral 262 
migratory stream, eventually reaching the brain stem. Microvascular pathology and ischemic brain injury 263 
develop only secondarily, after vasogenic oedema formation (Hoffmann et al., 2016). Additional MRI studies 264 
are currently underway in CM patients from Asia and Africa, and are aiming to elucidate these pathogenetic 265 
processes (Wassmer et al., 2015). 266 
 267 
6. New adjunct therapies and critical care approaches in severe malaria 268 
Even under optimal conditions, the case–fatality rate in severe malaria treated with either artemisinin 269 
derivatives or quinine remains high. In addition, multi-drug-resistant falciparum malaria is increasingly difficult 270 
to treat and new effective antimalarial agents are not expected to become available within the next few years. 271 
In an effort to reduce malaria-related mortality, numerous adjunctive therapies that may alter severe malaria-272 
induced physiological abnormalities are being evaluated, some of which have been described in other sections 273 
of this review. Such therapies are, in nature, highly specific to distinct syndromes of severe malaria, as their 274 
aim is to target precise pathophysiological processes. For example, protein C system defects inflicted by 275 
the malaria parasite protein PfEMP1 in CM can be overcome by a soluble EPCR variant (Petersen et al., 276 
2015), and could therefore represent a revolutionary approach to dampen the pathogenetic mechanisms and 277 
decrease mortality in affected patients. Promising advances in adjunct therapies for other severe malaria 278 
syndromes such as acute respiratory distress, acute kidney injury, severe anaemia and metabolic acidosis are 279 
still lacking.  280 
The potential clinical benefit of fluid resuscitation was recently investigated and liberal fluid loading in adults 281 
with severe malaria showed no improvement in the acidosis and acute kidney injury, but increased the 282 
incidence of acute pulmonary oedema (Hanson et al., 2014). However, a more conservative fluid strategy, 283 
using a simple weight-based algorithm, led to a low incidence of acute respiratory distress without significant 284 
deterioration in acid-base status, renal function, electrolyte profile or systemic haemodynamics, and was 285 
associated with increased survival (Aung et al., 2015). 286 
In addition to P. falciparum, severe cases of P. vivax and P. knowlesi have also been reported, although 287 
sequestration is not a specific feature of either infection and the relative contribution of co-morbidities to clinical 288 
manifestations, particularly in vivax malaria, remains to be investigated (Wassmer et al., 2015). Both parasitic 289 
infections can cause acute pulmonary oedema with a clinical phenotype similar to that seen in severe 290 
falciparum malaria. No studies of fluid resuscitation have been performed in these patients, but those are 291 
warranted. 292 
 293 
7. Novel parasite factors involved in malarial pathogenesis and possible therapeutic targets  294 
In parallel to the development of adjunct therapies, a growing effort in the search for new and effective 295 
pharmacotherapies has been triggered by the emergence of multi-drug resistance in P. falciparum. While still 296 
in their infancy, these approaches are promising and provide a wide range of new therapeutic targets. Several 297 
new parasite factors were recently identified and have emerged as potential drug target candidates. Among 298 
those, G-quadruplex (G4) DNA motifs and RecQ helicases are newly described players in virulence gene 299 
control in P. falciparum. G4s are four-stranded structures formed by the stacking of quartets of guanines, and 300 
recent work has shown that they can form in vivo as well as in vitro, affecting DNA replication, transcription, 301 
translation and telomere maintenance. Harris and Merrick (2015) first demonstrated that DNA helicases, as 302 
well as histone-modifying proteins, can influence var gene dynamics in P. falciparum. Understanding the G4-303 
mediated regulation of the parasite virulence may open the door to novel therapeutic interventions. 304 
Plasmodium falciparum exports parasite-encoded proteins involved in structural and functional remodelling 305 
of the host cell. This process is essential for the development of the parasite and is also associated with its 306 
virulence (Maier et al., 2009). Molecular chaperones of the heat shock protein (Hsp) family are prominent 307 
members of the exportome, including various Hsp40s and one Hsp70. The first biochemical evidence for a 308 
specific functional co-chaperone interaction between the exported malarial PFA0660w and PfHsp70-x was 309 
recently reported (Daniyan et al., 2016). PFA0660w can stimulate the ATPase activity of PfHsp70-x and work 310 
additively with it in a co-chaperone/chaperone interaction, resulting in protein aggregation suppression. The 311 
authors also showed that PFA0660w could potentially act independently as a chaperone. These findings 312 
support the proposed role of PfHsp70-x and PFA0660w in parasite protein trafficking and folding in IEs. Further 313 
studies are underway to determine the molecular basis for the specificity of this interaction, and to identify 314 
inhibitors capable of disrupting it. All of the modifications to the IEs are induced by parasite proteins, most of 315 
which initially traffic from the parasite via the secretory pathway to the parasitophorous vacuole. There, 316 
proteins interact with a translocon complex called PTEX (Plasmodium translocon of exported proteins) that 317 
transports them across the vacuole membrane into the IE. Blocking protein export through blocking PTEX 318 
function leads to the arrest of parasite growth and loss of virulence (Kalanon et al., 2016), making PTEX an 319 
excellent drug target (Gilson et al., 2016). 320 
Post-translational modification of histones is one of the key gene regulation mechanisms during the intra-321 
erythrocyte development cycle of P. falciparum. Studies of proteins, which recognise and interact with histone 322 
post-translational modifications, are pivotal for understanding P. falciparum pathogenesis. Bromodomain 323 
proteins bind to acetylated lysines, often on histones, and frequently play a role in regulation of gene 324 
expression. Plasmodium falciparum-specific bromodomain protein 1 (PfBDP1) binds to chromatin at 325 
transcriptional start sites of invasion-related genes and directly controls their expression. Conditional PfBDP1 326 
knockdown causes a significant defect in parasite invasion and growth (Josling et al., 2015). In parallel to these 327 
studies, several small molecule inhibitors have recently been reported to have a high affinity and specificity to 328 
bromodomains, and could represent a new therapeutic avenue in P. falciparum infection (Padmanabhan et al., 329 
2016).   330 
The unique plasticity of the epigenetic regulation in P. falciparum has also emerged as a pivotal virulence 331 
and pathogenicity factor in recent years. Karmodyia et al. (2015) performed genome-wide mapping of multiple 332 
histone modifications of P. falciparum and reported H3K36me2 as a global repressive mark, with gene 333 
regulation being fine-tuned by the ratio of activation marks to H3K36me2 (Karmodiya et al., 2015). 334 
Moreover, var genes are mostly poised and marked by a unique set of activation (H4ac) and repression 335 
(H3K9me3) marks, which are mutually exclusive to other P. falciparum housekeeping genes. A better 336 
characterization of epigenetic regulation in P. falciparum will lead to the identification of potential therapeutic 337 
targets (Ay et al., 2015). Indeed, disrupting the function of proteins responsible for maintaining 338 
heterochromatin, such as HP1 (Brancucci et al., 2014), could be an effective strategy to block parasite 339 
replication during the asexual cycle. PfAP2-G, a transcription factor shown to drive gametocytogenesis, also 340 
represents a promising target to disrupt malaria transmission (Coleman et al., 2014). Extensive 341 
characterisations of the parasite epigenetic factors, as well as its post-transcriptional and translational control 342 
processes, are likely to open new avenues for drug development against P. falciparum. 343 
 344 
8. Pathologies other than CM: MiP 345 
Plasmodium falciparum infection during pregnancy can result in MiP, a pathology resulting fromcaused by 346 
the accumulation of IEs in the placental intervillous space and the infiltration of maternal 347 
monocytes/macrophages (Rogerson et al., 2003), with detrimental outcomes for both the mother and the 348 
foetus. Expression of PfEMP1-var2csa at the surface of IEs mediates their adhesion to the placenta. Adaptive 349 
immunity is progressively acquired during sequential malaria infections in pregnancy and is mediated by the 350 
production of anti-VAR2CSA antibodies, which promote IE adhesion blocking and opsonisation (Desai et al., 351 
2007). This naturally acquired immunity is the key basis for development of a vaccine to protect women during 352 
pregnancy, and VAR2CSA is currently the leading candidate (Fried and Duffy, 2015). However, recent findings 353 
indicate that broadly neutralising antibodies of multigravidae are not depleted on VAR2CSA recombinant 354 
antigens. Using a new approach to assess VAR2CSA domains for functional epitopes recognized by naturally 355 
acquired antibodies, Doritchamou et al. (2016) recently demonstrated that different Duffy binding-like (DBL) 356 
domain-specific IgG could react to both homologous as well as heterologous antigens and parasites, 357 
suggesting that conserved epitopes are shared between allelic variants. In addition, IE binding was blocked by 358 
ID1-DBL2-ID2a, DBL4 and DBL5-specific IgG, while partial cross-inhibition activity was observed with purified 359 
IgG specific to ID1-DBL2-ID2a and DBL4 antigens. Interestingly, plasma from patients still showed broadly 360 
adherence-blocking activity after complete depletion of these VAR2CSA specificities. These results suggest 361 
that VAR2CSA vaccines based on a single construct and variant might induce antibodies with limited broad 362 
blocking activity, and confirm that a multivalent vaccine comprised of up to five different alleles or with the 363 
addition of multiple placental malaria vaccine candidates may be needed to elicit the broad blocking activity 364 
observed in African multigravidae (Avril et al., 2010; Hommel et al., 2010). 365 
The generation of protective vaccines is becoming a priority, especially in areas where the prevalence of 366 
malaria has decreased due to control and elimination campaigns. Indeed, a recent study conducted in 367 
Mozambique showed a close relationship between antibody levels and the intensity of malaria transmission. 368 
Mayor et al. (2015) showed convincing evidence that a decline in the prevalence of malaria documented in the 369 
study area was accompanied by reductions in levels of IgG antibodies not only against VAR2CSA, but also 370 
against non-pregnancy-specific malaria antigens. In pregnant women with MiP, this was associated with an 371 
increase in parasite densities and a higher adverse effect of P. falciparum infection on maternal haemoglobin 372 
levels and newborn weights (Mayor et al., 2015). Although they also suggest that immunity may be regained as 373 
exposure increases, the findings of this study indicate that malaria control and elimination programmes could 374 
precede a resurgence of pregnancy-associated malaria pathologies. 375 
Additionally, MiP has also recently been linked to placental pathology in a low malaria transmission area in 376 
Brazil, where P. vivax is predominant (Souza et al., 2013). While MiP was not associated with severe outcome 377 
in a second study performed by the same team in this region, an increased ratio of peripheral receptor tyrosine 378 
kinase Tie-2 to angiopoetin (Ang-1) was associated with the occurrence of MiP. Both Ang-1 and Ang-2 had 379 
similar magnitudes but inverse associations with placental barrier thickness. MiP is an effect modifier of the 380 
association between Ang-1 and placental barrier thickness (Ataide et al., 2015). These findings provide a 381 
possible pathway through which placental pathological changes occur during MiP. 382 
Lastly, further to imbalances in cytokine cascades, IE cytoadhesion and angiogenic dysregulation, 383 
excessive or dysregulated complement activation as part of the host innate immune response to malaria 384 
infection can also exacerbate the severity of MiP, leading to poor pregnancy outcomes (McDonald et al., 385 
2015b). Using an experimental model of MiP in conjunction with micro-CT and HPLC analysis of 386 
neurotransmitter levels, McDonald et al. (2015a) showed that complement activation, in particular C5a, 387 
contributes to foetal neuropathologic outcomes during MiP. The offspring of infected animals showed 388 
persistent neurocognitive deficits in memory and affective-like behaviour compared with unexposed controls 389 
(McDonald et al., 2015a). These impairments were linked with decreased tissue levels of neurotransmitters in 390 
regions of the brain associated with the deficits. The inhibition of maternal C5a complement receptor signaling 391 
restored the levels of neurotransmitters and reversed the associated phenotype, suggesting new targets for 392 
intervention in MiP aimed at decreasing foetal neuropathologic outcomes. 393 
 394 
9. New investigative tools and experimental models 395 
A vast array of new tools and models has recently become available to facilitate the investigation of severe 396 
malaria pathogenesis, with a particular focus on CM. These are detailed elsewhere (Sahu et al., 2015). Further 397 
to this, the rise of the ‘omic’ era during the past decade has provided the malaria research community with 398 
unprecedented approaches and technologies to better understand the biology, evolution and pathogenesis of 399 
different Plasmodium spp. The Malaria Host-Pathogen Interaction Centre (MaHPIC) is a large international 400 
systems biology consortium developed in 2012 and based in the USA 401 
(http://www.systemsbiology.emory.edu/index.html), which allowed the development of a variety of distinctive 402 
hypothesis-generating and hypothesis-driven collaborations with scientific teams in malaria-endemic regions. 403 
These collaborations involve investigators from several countries in South America, southeastern Asia and 404 
sub-Saharan Africa, with a focus on infections caused by the predominant, less predominant, or mixed species 405 
of Plasmodium (Anderson et al., 2015; Lapp et al., 2015), to study disease states, pathogenesis and 406 
physiological or immunobiological questions through the use of untargeted high-resolution metabolomics, as 407 
well as clinical and demographic metadata (Salinas et al., 2014). In addition, the MaHPIC team is intensively 408 
studying malaria using non-human primate model systems (macaque and New World monkey species, (Joyner 409 
et al., 2015)). An overarching goal, beyond the team’s specific research quests, is to develop and make 410 
available unique large ‘omic’ datasets (e.g., transcripts, proteins, lipids, metabolites and immune responses), 411 
integrated models and tools for the use and benefit of the research community at large. This unique and 412 
integrated combination of ‘omic’ approaches represents a revolutionary platform to identify, develop and 413 
evaluate new diagnostic tools, antimalarial drugs and vaccines for different types of malaria parasites.  414 
In parallel, live imaging, including multi-photon approaches, has contributed to the understanding of CM 415 
pathogenesis, notably its haemodynamics (Nacer et al., 2014) and its immune cell mobilisation (Pai et al., 416 
2014) components. Recently, in experimental CM, vibrational spectroscopies provided evidence of 417 
peroxidative stress and protein oxidation within cerebellar gray matter, which were co-localised with elevated 418 
non-haeme iron at the site of microhaemorrhages. A novel combination of chemical probe-free, multimodal 419 
imaging to quantify molecular markers of disturbed energy metabolism and peroxidative stress thus provides 420 
new insights into understanding CM pathogenesis (Hackett et al., 2015). 421 
 422 
10. Conclusions and future perspectives  423 
Despite the recent leap in our understanding of pathogenetic mechanisms leading to severe malaria, the 424 
translational outputs to improve the clinical outcome of patients remain meager. Collaborative and 425 
multidisciplinary approaches using clinical samples from field sites in endemic areas, in vitro and ex vivo 426 
models, as well as animal models of the disease, are crucial to allow global advances in the fight not only 427 
against severe falciparum malaria, but also emerging public health issues such as severe malaria caused by P. 428 
vivax and P. knowlesi.  429 
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